These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Overcoming multidrug resistance in taxane chemotherapy. Geney R; Ungureanu lM; Li D; Ojima I Clin Chem Lab Med; 2002 Sep; 40(9):918-25. PubMed ID: 12435109 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models. Yee SS; Risinger AL Molecules; 2021 Jul; 26(13):. PubMed ID: 34279417 [TBL] [Abstract][Full Text] [Related]
24. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression. Heuer TS; Ventura R; Mordec K; Lai J; Fridlib M; Buckley D; Kemble G EBioMedicine; 2017 Feb; 16():51-62. PubMed ID: 28159572 [TBL] [Abstract][Full Text] [Related]
25. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. Karp JE; Lancet JE Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662 [TBL] [Abstract][Full Text] [Related]
26. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Dumontet C; Isaac S; Souquet PJ; Bejui-Thivolet F; Pacheco Y; Peloux N; Frankfurter A; Luduena R; Perol M Bull Cancer; 2005 Feb; 92(2):E25-30. PubMed ID: 15749640 [TBL] [Abstract][Full Text] [Related]
27. Fluorescent taxoids as probes of the microtubule cytoskeleton. Evangelio JA; Abal M; Barasoain I; Souto AA; Lillo MP; Acuña AU; Amat-Guerri F; Andreu JM Cell Motil Cytoskeleton; 1998; 39(1):73-90. PubMed ID: 9453715 [TBL] [Abstract][Full Text] [Related]
28. Survival following the documentation of platinum and taxane resistance in ovarian cancer. Büyükçelik A; Yalçin B; Utkan G; Doruk H Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006 [No Abstract] [Full Text] [Related]
29. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695 [TBL] [Abstract][Full Text] [Related]
30. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195 [TBL] [Abstract][Full Text] [Related]
31. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215 [TBL] [Abstract][Full Text] [Related]
32. Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer. Wlodarczyk N; Le Broc-Ryckewaert D; Gilleron P; Lemoine A; Farce A; Chavatte P; Dubois J; Pommery N; Hénichart JP; Furman C; Millet R J Med Chem; 2011 Mar; 54(5):1178-90. PubMed ID: 21299244 [TBL] [Abstract][Full Text] [Related]
33. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis. Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942 [TBL] [Abstract][Full Text] [Related]
34. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer. Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449 [TBL] [Abstract][Full Text] [Related]
35. Laulimalide and synthetic laulimalide analogues are synergistic with paclitaxel and 2-methoxyestradiol. Clark EA; Hills PM; Davidson BS; Wender PA; Mooberry SL Mol Pharm; 2006; 3(4):457-67. PubMed ID: 16889440 [TBL] [Abstract][Full Text] [Related]
36. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers. Wang R; Wang H; Wang Z J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508 [TBL] [Abstract][Full Text] [Related]
37. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943 [TBL] [Abstract][Full Text] [Related]
38. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis. Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235 [TBL] [Abstract][Full Text] [Related]
39. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. Zhou J; Vos CC; Gjyrezi A; Yoshida M; Khuri FR; Tamanoi F; Giannakakou P J Biol Chem; 2009 Apr; 284(15):9648-55. PubMed ID: 19228685 [TBL] [Abstract][Full Text] [Related]
40. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]